Cell and Gene Therapy Products
This article was originally published in SRA
Executive Summary
French regulations posted on AFSSaPS website
You may also be interested in...
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Regulatory Science Tools For Phantoms, Lab Methods Added To US FDA Catalog
The regulatory tools are for use in medical device development.
FDA To Hold Postponed 3-Day Pediatric Device Workshop In February
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: